Ruxolitinib passes another PhIII test for graft-versus-host disease, a win for Incyte and Novartis
Ruxolitinib has proven itself a stellar moneymaker for Incyte and Novartis, and it should come as no surprise that the drug’s efficacy reached expectations …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
